ImmunoGen, Inc. chalked up a clear victory in the confirmatory Phase III MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) among pretreated patients with folate receptor alpha (FRα)-positive platinum chemotherapy-resistant ovarian cancer, as the drug became the first to demonstrate an overall survival (OS) advantage in that population. The company sees the data as enabling it to extend the drug’s reach into Europe while also building confidence in its ability to expand into other ovarian cancer subpopulations.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?